Dynavax Technologies | DVAX - Net Income



Dynavax Technologies reported $18.72M in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
AbbVie USD 938M 348M Jun/2025
Adma Biologics USD 34.22M 77.68M Jun/2025
Amgen USD 1.43B 298M Jun/2025
AstraZeneca USD 2.45B 466M Jun/2025
Biogen USD 634.8M 394.3M Jun/2025
BioMarin Pharmaceutical USD 240.53M 54.85M Jun/2025
Bristol-Myers Squibb USD 1.31B 1.15B Jun/2025
Dynavax Technologies USD 18.72M 114.82M Jun/2025
Gilead Sciences USD 1.96B 645M Jun/2025
Glaxosmithkline GBP 1.44B 1.03B Jun/2025
Merck USD 4.43B 652M Jun/2025
Neurocrine Biosciences USD 107.5M 99.6M Jun/2025
Novartis USD 4.02B 418M Jun/2025
Pfizer USD 2.91B 58M Jun/2025
Regeneron Pharmaceuticals USD 1.39B 582.9M Jun/2025
Roche Holding CHF 1.01B 2.12B Dec/2024
Sarepta Therapeutics USD 196.89M 644.4M Jun/2025
TG Therapeutics USD 28.19M 23.13M Jun/2025
Vertex Pharmaceuticals USD 1.03B 386.6M Jun/2025